Literature DB >> 8250240

Testing potential gyrase inhibitors of bacterial DNA gyrase: a comparison of the supercoiling inhibition assay and "cleavable complex" assay.

J F Barrett1, J I Bernstein, H M Krause, J J Hilliard, K A Ohemeng.   

Abstract

Inhibitory activity of test compounds against Escherichia coli DNA gyrase in a "cleavable complex" assay, readily observed in vitro at the enzyme level by the artificial addition of a denaturing agent, is found to be an excellent indicator of 4-quinolone inhibition of DNA gyrase, and as accurate a predictor of target enzyme inhibitory activity as the measurement of the inhibition of DNA gyrase supercoiling. This study was designed to examine the specificity of DNA gyrase inhibitors of various chemical classes in these two DNA gyrase assays, and define the use of these two assays in understanding the nature of inhibition by experimental compounds. Supercoiling inhibition was detected by determination of the 50% inhibition level, and cleavable complex inhibition measured by the determination of the drug concentration at which 50% of the maximal (of control) formation of linear, cleaved DNA was obtained. Results indicate that these two assays can serve several different functions in microbiological research, among them: (1) quantitation of enzyme inhibitory activity at the target level; and (2) distinguishing between nonspecific inhibition or artifactual inhibition of DNA gyrase and true, mechanism-based inhibition of the catalytic activity of DNA gyrase.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8250240     DOI: 10.1006/abio.1993.1493

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  9 in total

1.  NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.

Authors:  Thomas J Dougherty; Asha Nayar; Joseph V Newman; Sussie Hopkins; Gregory G Stone; Michele Johnstone; Adam B Shapiro; Mark Cronin; Folkert Reck; David E Ehmann
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

2.  Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.

Authors:  Stéphanie Matrat; Stéphanie Petrella; Emmanuelle Cambau; Wladimir Sougakoff; Vincent Jarlier; Alexandra Aubry
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

3.  Mechanism of action of the des-F(6) quinolone BMS-284756 measured by supercoiling inhibition and cleavable complex assays.

Authors:  P Wu; L E Lawrence; K L Denbleyker; J F Barrett
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

4.  Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?

Authors:  Stéphanie Matrat; Emmanuelle Cambau; Vincent Jarlier; Alexandra Aubry
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

5.  Unique biological properties and molecular mechanism of 5,6-bridged quinolones.

Authors:  David R Macinga; Paul J Renick; Kelly M Makin; David H Ellis; Allison A Kreiner; Min Li; Kirk J Rupnik; Erica M Kincaid; Cynthia D Wallace; Benoit Ledoussal; Timothy W Morris
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

6.  Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.

Authors:  Jijun Cheng; Jane A Thanassi; Christy L Thoma; Barton J Bradbury; Milind Deshpande; Michael J Pucci
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191

7.  Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.

Authors:  Alexandra Aubry; Xiao-Su Pan; L Mark Fisher; Vincent Jarlier; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

8.  Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.

Authors:  Hans H Locher; Patrick Caspers; Thierry Bruyère; Susanne Schroeder; Philippe Pfaff; Andreja Knezevic; Wolfgang Keck; Daniel Ritz
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

9.  Bioactivity of Isostructural Hydrogen Bonding Frameworks Built from Pipemidic Acid Metal Complexes.

Authors:  Paula C Alves; Patrícia Rijo; Catarina Bravo; Alexandra M M Antunes; Vânia André
Journal:  Molecules       Date:  2020-05-20       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.